{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-016524","form_type":"8-K","ticker":null,"cik":"0001838821","company_name":"ARYA Sciences Acquisition Corp IV","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.056764+00:00","generated_at":"2026-06-17T06:02:20.069477+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARYA Sciences restates Q3 2022 financials; underwriter commission waiver misclassified as gain rather than equity credit","bullets":["Restating Q3 2022 financials because extinguishment of deferred underwriter commissions was incorrectly recorded as a gain instead of a credit to shareholders' deficit.","No impact on liquidity, cash flows, trust account or operating expenses — only a classification change.","Identified a material weakness in internal control over financial reporting and ineffective disclosure controls for the affected period.","Restatement will be included in the 2022 10-K; audit committee and independent auditor have been informed.","One underwriter waived its 50% share of deferred underwriting commissions in August 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-016524","json":"https://secwatch.observer/filing/0001140361-23-016524.json","markdown":"https://secwatch.observer/filing/0001140361-23-016524.md","text":"https://secwatch.observer/filing/0001140361-23-016524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838821/000114036123016524/0001140361-23-016524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838821/000114036123016524/brhc10050928_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:02:20.069477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22c691569eecb54115c3c9f8bbb3331577dba3eb","claim":"ARYA Sciences Acquisition Corp IV reported that prior financial statements should not be relied upon.","evidence_excerpt":"the Company’s management and the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) concluded on April 4, 2023 that the financial statements for the Affected Period (as defined below) included in the Quarterly Report should no longer be relied upon","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1838821/000114036123016524/0001140361-23-016524-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"},{"label":"Auditor","value":"WithumSmith+Brown, PC"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}